Proproten-100 in the therapy of patients with the alcohol withdrawal syndrome.

The efficiency of Proproten-100 containing antibodies to S100 protein in ultralow doses and used to relieve somatovegetative and psychoneurological manifestations of the alcohol withdrawal syndrome was studied in a double-blind, placebo-controlled clinical trial. The preparation possessed anxiolytic, sedative, hypnagogic, and vegetostabilizing properties. Proproten-100 more rapidly relieved the alcohol withdrawal syndrome than standard drugs (by 2 times).

Structure and correlates of alcohol dependence in clinical samples in the United States and Russia.

Using items from the Composite International Diagnostic Interview, dimensionality of the alcohol dependence syndrome was assessed in clinical samples in the United States and Russia. In both groups, a single-factor model provided a high degree of goodness of fit thus demonstrating cross-cultural coherence of the construct. The item dealing with narrowing of the drinking repertoire is most disparate in each sample.